Lantheus Holdings, Inc. (NASDAQ:LNTH) Insider Daniel Niedzwiecki Sells 1,380 Shares

Lantheus Holdings, Inc. (NASDAQ:LNTHGet Rating) insider Daniel Niedzwiecki sold 1,380 shares of the stock in a transaction dated Wednesday, May 18th. The stock was sold at an average price of $64.54, for a total value of $89,065.20. Following the transaction, the insider now owns 71,143 shares of the company’s stock, valued at approximately $4,591,569.22. The transaction was disclosed in a filing with the SEC, which is available at this link.

Daniel Niedzwiecki also recently made the following trade(s):

  • On Tuesday, March 1st, Daniel Niedzwiecki sold 2,645 shares of Lantheus stock. The stock was sold at an average price of $48.04, for a total value of $127,065.80.

Shares of Lantheus stock traded down $1.00 during trading on Friday, hitting $62.29. 906,088 shares of the stock were exchanged, compared to its average volume of 1,059,237. The company has a current ratio of 1.83, a quick ratio of 1.64 and a debt-to-equity ratio of 0.31. The company has a fifty day moving average price of $58.87 and a 200-day moving average price of $40.25. The stock has a market capitalization of $4.28 billion, a price-to-earnings ratio of -109.28, a price-to-earnings-growth ratio of 0.66 and a beta of 0.76. Lantheus Holdings, Inc. has a 1-year low of $19.30 and a 1-year high of $69.74.

Lantheus (NASDAQ:LNTHGet Rating) last announced its quarterly earnings results on Friday, April 29th. The medical equipment provider reported $0.97 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.51. Lantheus had a positive return on equity of 19.83% and a negative net margin of 6.89%. The firm had revenue of $208.90 million for the quarter, compared to the consensus estimate of $165.30 million. During the same quarter in the previous year, the business earned $0.05 earnings per share. The business’s revenue was up 125.8% compared to the same quarter last year. Equities research analysts forecast that Lantheus Holdings, Inc. will post 2.78 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of LNTH. Principal Financial Group Inc. boosted its position in Lantheus by 17.0% during the fourth quarter. Principal Financial Group Inc. now owns 555,077 shares of the medical equipment provider’s stock worth $16,036,000 after purchasing an additional 80,665 shares during the period. BNP Paribas Arbitrage SA grew its stake in Lantheus by 153.9% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 69,561 shares of the medical equipment provider’s stock valued at $1,786,000 after buying an additional 42,166 shares during the last quarter. AXA S.A. bought a new position in Lantheus in the 3rd quarter valued at about $516,000. Russell Investments Group Ltd. lifted its position in Lantheus by 56.0% during the fourth quarter. Russell Investments Group Ltd. now owns 1,262,121 shares of the medical equipment provider’s stock worth $36,459,000 after acquiring an additional 452,820 shares during the last quarter. Finally, First Manhattan Co. boosted its holdings in shares of Lantheus by 39.5% during the third quarter. First Manhattan Co. now owns 4,324 shares of the medical equipment provider’s stock worth $111,000 after acquiring an additional 1,224 shares during the period. Institutional investors and hedge funds own 97.14% of the company’s stock.

LNTH has been the subject of a number of recent research reports. Truist Financial upped their price target on Lantheus from $77.00 to $94.00 in a research report on Monday, May 2nd. B. Riley began coverage on shares of Lantheus in a research note on Monday, May 9th. They issued a “buy” rating and a $91.00 price target on the stock. Zacks Investment Research upgraded shares of Lantheus from a “sell” rating to a “hold” rating and set a $74.00 price objective for the company in a research note on Tuesday, May 3rd. started coverage on Lantheus in a research report on Thursday, March 31st. They issued a “hold” rating on the stock. Finally, SVB Leerink increased their price target on Lantheus from $34.00 to $75.00 and gave the company an “outperform” rating in a research report on Thursday, February 24th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, Lantheus has an average rating of “Buy” and a consensus target price of $83.50.

About Lantheus (Get Rating)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.

Recommended Stories

Insider Buying and Selling by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with's FREE daily email newsletter.